Literature DB >> 23302660

Decline in cognitive function over 18 months in healthy older adults with high amyloid-β.

Kathryn A Ellis1, Yen Ying Lim, Karra Harrington, David Ames, Ashley I Bush, David Darby, Ralph N Martins, Colin L Masters, Christopher C Rowe, Greg Savage, Cassandra Szoeke, Victor L Villemagne, Paul Maruff.   

Abstract

We aimed to characterize the nature and magnitude of cognitive decline in a group of healthy older adults with high and low levels of amyloid-β (Aβ) and who were APOE ε4 carriers and non-carriers. Healthy older adults underwent positron emission tomography neuroimaging for Aβ, APOE genotyping, and cognitive and clinical assessment as part of their baseline assessment in the Australian Imaging, Biomarker, and Lifestyle study. Cognitive function and clinical ratings were reassessed 18 months later. Linear mixed model analyses adjusted for baseline cognitive function indicated that relative to healthy older adults with low Aβ, healthy older adults with high Aβ showed greater decline in episodic memory and language at 18 months. No decline on any measure of executive function, attention, or clinical rating was observed for healthy older adults with high Aβ levels. Compared to non-carriers, APOE ε4 carriers showed a greater decline only on the task of visual memory at the 18 month assessment. Importantly though, no interaction between APOE ε4 and Aβ was observed on any measure of cognitive function. The results of this study suggest that high Aβ load was associated with greater decline in episodic memory and language, that the magnitude of this decline was moderate and equivalent across both domains, and that APOE ε4 carriage did not moderate the relationship between Aβ and decline in memory and language functions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23302660     DOI: 10.3233/JAD-122170

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  21 in total

1.  Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study.

Authors:  Andrew J Aschenbrenner; David A Balota; Anne M Fagan; Janet M Duchek; Tammie L S Benzinger; John C Morris
Journal:  J Int Neuropsychol Soc       Date:  2015-09       Impact factor: 2.892

2.  Sensitivity of negative subsequent memory and task-negative effects to age and associative memory performance.

Authors:  Marianne de Chastelaine; Julia T Mattson; Tracy H Wang; Brian E Donley; Michael D Rugg
Journal:  Brain Res       Date:  2014-09-28       Impact factor: 3.252

3.  An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.

Authors:  Jessica B Langbaum; Suzanne B Hendrix; Napatkamon Ayutyanont; Kewei Chen; Adam S Fleisher; Raj C Shah; Lisa L Barnes; David A Bennett; Pierre N Tariot; Eric M Reiman
Journal:  Alzheimers Dement       Date:  2014-04-21       Impact factor: 21.566

Review 4.  Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan.

Authors:  Marine Fouquet; Florent L Besson; Julie Gonneaud; Renaud La Joie; Gaël Chételat
Journal:  Neuropsychol Rev       Date:  2014-08-22       Impact factor: 7.444

5.  Diffusion Tensor Imaging Predictors of Episodic Memory Decline in Healthy Elders at Genetic Risk for Alzheimer's Disease.

Authors:  Melissa A Lancaster; Michael Seidenberg; J Carson Smith; Kristy A Nielson; John L Woodard; Sally Durgerian; Stephen M Rao
Journal:  J Int Neuropsychol Soc       Date:  2016-11       Impact factor: 2.892

Review 6.  The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.

Authors:  Napatkamon Ayutyanont; Jessica B S Langbaum; Suzanne B Hendrix; Kewei Chen; Adam S Fleisher; Michel Friesenhahn; Michael Ward; Camilo Aguirre; Natalia Acosta-Baena; Lucìa Madrigal; Claudia Muñoz; Victoria Tirado; Sonia Moreno; Pierre N Tariot; Francisco Lopera; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2014-06       Impact factor: 4.384

7.  Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's disease.

Authors:  Adam P Mecca; Nicole M Barcelos; Shuo Wang; Anna Brück; Nabeel Nabulsi; Beata Planeta-Wilson; Jennifer Nadelmann; Amanda L Benincasa; Jim Ropchan; Yiyun Huang; Joel Gelernter; Peter H Van Ness; Richard E Carson; Christopher H van Dyck
Journal:  Neurobiol Aging       Date:  2017-10-06       Impact factor: 4.673

8.  How technology is reshaping cognitive assessment: Lessons from the Framingham Heart Study.

Authors:  Rhoda Au; Ryan J Piers; Sherral Devine
Journal:  Neuropsychology       Date:  2017-11       Impact factor: 3.295

9.  A pilot study of neuropsychological functions, APOE and amyloid imaging in patients with gliomas.

Authors:  D D Correa; M Kryza-Lacombe; X Zhou; R E Baser; B J Beattie; Z Beiene; J Humm; L M DeAngelis; I Orlow; W Weber; J Osborne
Journal:  J Neurooncol       Date:  2017-11-22       Impact factor: 4.130

10.  Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study.

Authors:  Lindsay R Clark; Annie M Racine; Rebecca L Koscik; Ozioma C Okonkwo; Corinne D Engelman; Cynthia M Carlsson; Sanjay Asthana; Barbara B Bendlin; Rick Chappell; Christopher R Nicholas; Howard A Rowley; Jennifer M Oh; Bruce P Hermann; Mark A Sager; Bradley T Christian; Sterling C Johnson
Journal:  Alzheimers Dement       Date:  2016-01-21       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.